Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2013-11-06 Delisting Announcement
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Marburger Schnelldiagnostik-Spezialist in Quotation Board einbezogen / Aufnahme im Xetra(R)-Handel
Delisting Announcement Classification · 99% confidence The document is a short corporate news release dated November 6, 2013, announcing that NanoRepro AG shares have been included in the Quotation Board of the Frankfurt Stock Exchange and will trade on Xetra(R) starting that day, with KochBank GmbH acting as the Designated Sponsor. This is a specific announcement regarding market listing and liquidity, not a comprehensive annual report (10-K), an earnings release (ER), or a formal dividend notice (DIV). It fits best under general regulatory announcements or news that doesn't fit a more specific category. Since it is a specific market/listing update that isn't covered by the other codes (like CAP for financing or DLST for delisting), the most appropriate general regulatory/news category is RNS (Regulatory Filings/Miscellaneous). Given the short length and the nature of the announcement (a market event update), RNS is the best fit as a catch-all for specific, non-standard corporate news.
2013-11-06 German
NanoRepro AG: Einbeziehung der Aktien in den m:access der Borse Munchen
Share Issue/Capital Change Classification · 95% confidence The document is a short corporate announcement dated October 1, 2013, detailing that NanoRepro AG's shares will be admitted to trading in the m:access segment of the Munich Stock Exchange starting October 2, 2013. Crucially, it mentions an upcoming capital increase via a subscription offer starting October 8, 2013, and states that the corresponding securities prospectus is published on the company website. The document itself is brief (4129 characters) and serves primarily to announce the listing change and the availability of the prospectus for the capital measure. This structure—announcing an event and referencing a formal document (prospectus) elsewhere—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the core event is related to capital structure/financing (the capital increase and listing change), and it is an announcement referencing a formal document (prospectus), it aligns best with 'Capital/Financing Update' (CAP) or 'Report Publication Announcement' (RPA). Given the explicit mention of the capital increase ('Kapitalerhöhung') and the reference to the published prospectus, 'CAP' is highly relevant, but the format is that of a news release announcing publication. However, the content is fundamentally about a capital measure. Since the document is short and announces the availability of a prospectus related to a capital measure, 'CAP' (Capital/Financing Update) is the most specific fit for the underlying corporate action, even if the delivery mechanism resembles an RPA.
2013-10-01 German
NanoRepro AG: NanoRepro AG beschliet Kapitalerhohung
Share Issue/Capital Change Classification · 99% confidence The document is a corporate news release dated September 27, 2013, titled "NanoRepro AG beschließt Kapitalerhöhung" (NanoRepro AG resolves capital increase). The text explicitly details the decision by the Management Board, with Supervisory Board approval, to increase the share capital via a rights offering to existing shareholders. It specifies the amount of increase, the subscription ratio (4 to 1), the subscription price (EUR 1.90), and the intended use of the proceeds (market expansion, product development). This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although a prospectus was mentioned, the document itself is the announcement of the capital increase, not the prospectus or a general regulatory filing.
2013-09-27 German
NanoRepro AG: Groauftrag steht unmittelbar vor der Auslieferung / Pharma-Spezialist in Kuwait bezieht deutsche Schnelltests fur EUR 200.000
Regulatory Filings Classification · 99% confidence The document is a short news release dated August 5, 2013, titled 'NanoRepro AG: Großauftrag steht unmittelbar vor der Auslieferung' (Major order is about to be delivered). It discusses a significant sales contract, strategic alliance, and the upcoming delivery of diagnostic tests worth EUR 200,000 to Kuwait. It mentions revenue development ('Umsatzentwicklung') and strategic decisions. This content strongly aligns with an Earnings Release (ER) which covers key financial highlights and business updates for a period, or potentially a Regulatory Filing (RNS) if it were purely informational. However, given the focus on a major contract fulfillment and revenue impact, it functions as an initial announcement of significant business/financial news, fitting the 'Earnings Release' definition better than a general regulatory filing, although it is short and resembles a press release. Since it is not a full report (like 10-K or IR) and announces specific business achievements/revenue drivers, ER is the most appropriate fit among the specific financial categories. It is not a formal report publication announcement (RPA) as it contains the substance, not just a notice about a report.
2013-08-05 German
NanoRepro AG: NanoRepro AG erschliet libyschen Markt: Schwangerschaftstests sind ausgeliefert, Marburger Schnelldiagnostik-Spezialist reicht Wertpapier-Prospekt ein
Capital/Financing Update Classification · 95% confidence The document is a short news release dated June 25, 2013, detailing two main events for NanoRepro AG: the delivery of pregnancy tests to Libya (a sales/revenue development) and the submission of a securities prospectus (Wertpapier-Prospekt) to BaFin to facilitate a switch to the Entry Standard for Xetra trading. The content focuses on business expansion and capital market activities. Since it announces a filing (prospectus submission) and discusses financing/capital structure goals, it aligns best with 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if the prospectus filing itself is the primary focus. However, the core theme is the strategic move related to capital markets and transparency, which strongly suggests a financing/capital structure event. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate fit for announcing the submission of a prospectus aimed at improving stock market access and transparency, which is a capital structure/financing related activity. It is not a full financial report (10-K, IR) or a simple dividend announcement (DIV). It is too specific for the general RNS fallback.
2013-06-25 German
NanoRepro AG: TV Prasenz steigert Umsatz Interesse an Schnelltests wachst
Regulatory Filings Classification · 99% confidence The document is a short news release dated May 21, 2013, titled 'NanoRepro AG: TV Präsenz steigert Umsatz Interesse an Schnelltests wächst'. It discusses a sudden increase in demand for the company's rapid tests following a television appearance and outlines plans for expanding their online strategy and product portfolio (HIV, Allergies). It concludes with standard boilerplate text indicating it is a 'Corporate News/Finanznachricht' distributed by DGAP. This format—a brief announcement highlighting recent business developments, sales spikes, and future plans, rather than a comprehensive financial statement (like 10-K or IR) or a formal regulatory filing—best fits the description of an Earnings Release (ER) if it were reporting results, or more generally, a Regulatory Filing (RNS) as a miscellaneous corporate announcement. Since it focuses on sales interest and strategic response rather than formal periodic financial results (like revenue/profit figures for a quarter), and it is not a presentation (IP) or a management discussion (MDA), the most appropriate general category for an unscheduled, non-specific corporate update distributed via a news wire service is Regulatory Filings (RNS). Given the content is a general business update and not a specific financial report, RNS is the best fit among the provided options.
2013-05-21 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.